Kristen A Clarkson
Overview
Explore the profile of Kristen A Clarkson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
319
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bernshtein B, Kelly M, Cizmeci D, Zhiteneva J, Macvicar R, Kamruzzaman M, et al.
Lancet Microbe
. 2024 Aug;
5(10):100889.
PMID: 39116906
Background: Shigella is the third leading global cause of moderate or severe diarrhoea among children younger than 5 years globally, and is the leading cause in children aged 24-59 months....
2.
Conti V, Rossi O, Clarkson K, Mancini F, Nakakana U, Sarakinou E, et al.
NPJ Vaccines
. 2024 Mar;
9(1):56.
PMID: 38459072
Shigella spp. are a leading bacterial cause of diarrhea. No widely licensed vaccines are available and there is no generally accepted correlate of protection. We tested a S. sonnei Generalized...
3.
Duplessis C, Clarkson K, Ross Turbyfill K, Alcala A, Gutierrez R, Riddle M, et al.
Vaccine
. 2023 Sep;
41(42):6261-6271.
PMID: 37666695
Shigella species cause severe disease among travelers to, and children living in, endemic countries. Although significant efforts have been made to improve sanitation, increased antibiotic resistance and other factors suggest...
4.
Ross Turbyfill K, Clarkson K, Oaks E, Zurawski D, Vortherms A, Kaminski R
mSphere
. 2023 Jun;
8(4):e0007323.
PMID: 37389412
The artificial invasin complex (Invaplex) vaccine is a subunit approach that effectively induces robust immunogenicity directed to serotype-specific lipopolysaccharide and the broadly conserved IpaB and IpaC proteins. One advantage of...
5.
Clarkson K, Porter C, Talaat K, Kapulu M, Chen W, Frenck Jr R, et al.
Curr Top Microbiol Immunol
. 2022 May;
445:257-313.
PMID: 35616717
Shigella-controlled human infection models (CHIMs) are an invaluable tool utilized by the vaccine community to combat one of the leading global causes of infectious diarrhea, which affects infants, children and...
6.
Ross Turbyfill K, Clarkson K, Oaks E, Kaminski R
Vaccines (Basel)
. 2022 Apr;
10(4).
PMID: 35455297
The invasin complex or Invaplex vaccine is a unique subunit approach to generate a protective immune response. Invaplex is a large, macromolecular complex consisting of the major antigens: lipopolysaccharide (LPS)...
7.
Frenck Jr R, Conti V, Ferruzzi P, Ndiaye A, Parker S, McNeal M, et al.
EClinicalMedicine
. 2021 Aug;
39:101076.
PMID: 34430837
Background: Shigellosis accounts for substantial morbidity and mortality worldwide and is the second most common cause of moderate and severe diarrhoea in children. Methods: This phase 2b study (NCT03527173), conducted...
8.
Clarkson K, Porter C, Talaat K, Frenck Jr R, Alaimo C, Martin P, et al.
mSphere
. 2021 Jul;
6(4):e0012221.
PMID: 34259559
spp. are a leading cause of diarrhea-associated global morbidity and mortality. Development and widespread implementation of an efficacious vaccine remain the best option to reduce -specific morbidity. Unfortunately, the lack...
9.
Talaat K, Alaimo C, Martin P, Louis Bourgeois A, Dreyer A, Kaminski R, et al.
EBioMedicine
. 2021 Apr;
66:103310.
PMID: 33862589
Background: Shigellosis is a major cause of moderate to severe diarrhoea and dysentery in children under 5 years of age in low and middle-income countries. The Flexyn2a vaccine conjugates the...
10.
Clarkson K, Talaat K, Alaimo C, Martin P, Louis Bourgeois A, Dreyer A, et al.
EBioMedicine
. 2021 Apr;
66:103308.
PMID: 33813141
Background: Diarrheal diseases are a leading cause of global morbidity and mortality affecting all ages, but especially children under the age of five in resource-limited settings. Shigella is a leading...